C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells
暂无分享,去创建一个
A. D. De Groot | T. Ross | P. Knopf | W. Martin | C. Boyle | L. Levitz | L. Moise | Ryan Tassone | Timothy J. Messitt | A. J. Vincelli | Anne Searls De Groot
[1] Leonard Moise,et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. , 2012, Clinical immunology.
[2] P. Sagoo,et al. Expression of complement components, receptors and regulators by human dendritic cells , 2011, Molecular Immunology.
[3] Leonard Moise,et al. Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine , 2011, Immunome research.
[4] D. Isenman,et al. A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d , 2011, Science.
[5] J. Forrester,et al. Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis , 2010, European journal of immunology.
[6] J. Ahearn,et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.
[7] Anne S De Groot,et al. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.
[8] D. Scott,et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.
[9] H. Siljander,et al. Autoimmune mechanisms in type 1 diabetes. , 2008, Autoimmunity reviews.
[10] A. D. De Groot,et al. Novel function of complement C3d as an autologous helper T cell target , 2008 .
[11] A. D. De Groot,et al. Novel function of complement C3d as an autologous helper T‐cell target , 2008, Immunology and cell biology.
[12] Roland Martin,et al. Multiple sclerosis: a complicated picture of autoimmunity , 2007, Nature Immunology.
[13] T. Boone,et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.
[14] William W. Kwok,et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.
[15] Wuding Zhou,et al. Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype1 , 2006, The Journal of Immunology.
[16] N. Greenspan,et al. Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement1 , 2005, The Journal of Immunology.
[17] Yong Hu,et al. Role of Complement Receptor Type 2 and Endogenous Complement in the Humoral Immune Response to Conjugates of Complement C3d and Pneumococcal Serotype 14 Capsular Polysaccharide , 2005, Infection and Immunity.
[18] B. Kyewski,et al. Self-representation in the thymus: an extended view , 2004, Nature Reviews Immunology.
[19] D. Karp,et al. Cutting Edge: C3d Functions as a Molecular Adjuvant in the Absence of CD21/35 Expression 1 , 2004, The Journal of Immunology.
[20] J. Sodroski,et al. Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.
[21] I. Jónsdóttir,et al. Mucosal Vaccination Against Encapsulated Respiratory Bacteria – New Potentials for Conjugate Vaccines? , 2003, Scandinavian journal of immunology.
[22] M. Bachmann,et al. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection , 2002, Nature Medicine.
[23] P. Geusens,et al. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. , 2001, Seminars in arthritis and rheumatism.
[24] A. Lucas,et al. Increased Immunogenicity and Induction of Class Switching by Conjugation of Complement C3d to Pneumococcal Serotype 14 Capsular Polysaccharide , 2001, Infection and Immunity.
[25] P. Kourilsky,et al. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. , 2000, Immunity.
[26] H. Kohler,et al. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide , 1998, Nature Biotechnology.
[27] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[28] Christopher C. Goodnow,et al. C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.
[29] D. Kioussis,et al. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. , 1995, Immunity.
[30] A. Ben-nun,et al. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)‐derived peptide: Preliminary analysis of MOG T cell epitopes , 1995, European journal of immunology.
[31] R. Diefenbach,et al. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2. , 1995, Journal of immunology.
[32] N. Cooper,et al. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. , 1994, Journal of immunology.
[33] John D Lambris,et al. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. , 1989, Journal of immunology.
[34] John D Lambris,et al. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[35] J. Berzofsky,et al. Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes , 2010 .
[36] T. Ross,et al. A minimum CR2 binding domain of C3d enhances immunity following vaccination. , 2006, Advances in experimental medicine and biology.
[37] A. D. De Groot,et al. Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. , 2003, Developments in biologicals.
[38] J. Berzofsky,et al. Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design , 2002 .
[39] D. Fearon,et al. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.
[40] Melinda Fitzgerald,et al. Immunol. Cell Biol. , 1995 .